

RECEIVED
CENTRAL FAX CENTER

SEP 13 2005

FACSIMILE COVER SHEET

LAW OFFICES OF
SYNNESTVEDT & LECHNER LLP
2600 ARAMARK Tower
1101 Market Street
Philadelphia, PA 19107-2950
Phone No.: (215) 923-4466
Facsimile No.: (215) 923-2189

PLEASE DELIVER THE FACSIMILE TRANSMITTED HEREWITH TO:Name: U. S. Patent and Trademark OfficeFrom: Jonathan M. Dermott, Ph.D.Re: U.S. Application No. 10/006,177Cytotoxic T-Lymphocyte-Inducing Immunogens for Prevention, Treatment, and Diagnosis of Cancer
S&L Docket No.: P30,631 USAA total of 9 page(s), including this cover sheet, will be transmitted.Confirmation copy sent: Yes XX NoName of Operator: Barbara G. MakariouDate Sent: September 13, 2005Facsimile No.: 1-571-273-8300REMARKS: *****OFFICIAL COMMUNICATION*****

THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE ADDRESSEE AND
MAY CONTAIN INFORMATION THAT IS PRIVILEGED AND CONFIDENTIAL. IF
YOU HAVE RECEIVED THIS MESSAGE IN ERROR PLEASE NOTIFY US BY
TELEPHONE IMMEDIATELY. TO DO SO, YOU MAY CALL US COLLECT.

RECEIVED
CENTRAL FAX CENTER

SEP 13 2005

LAW OFFICES OF
SYNNESTVEDT & LECHNER LLP
 2600 ARAMARK TOWER
 1101 MARKET STREET
 PHILADELPHIA, PA 19107-2950
 TELEPHONE (215) 923-4466
 FAXSIMILE (215) 923-2189
 E-MAIL bynlech@synnlech.com
www.synnlech.com

OFFICIAL COMMUNICATION

September 13, 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of Venky Ramakrishna, Mark M. Ross,
 and Ramila Philip
 Application No. 10/006,177
 Filed December 4, 2001

Examiner: M. Yu, Ph.D.
 Group Art Unit: 1642
 Confirmation No. 2918

**CYTOTOXIC T-LYMPHOCYTE-INDUCING IMMUNOGENS FOR
 PREVENTION, TREATMENT, AND DIAGNOSIS OF CANCER**

(Atty. Docket No. P30,631 USA)

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office to
 facsimile number 571-273-8300 on September 13, 2005.


 Barbara G. Makarou
AMENDMENT UNDER 37 C.F.R. §1.111

Sir:

In response to the Examiner's interview, dated September 12, 2005, the following
 amendments and remarks are respectfully submitted.

Amendments to the Claims begin on page 2 of this paper.

Remarks begin on page 8 of this paper.